Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.

<h4>Background</h4>Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zuzana Zakostelska, Miloslav Kverka, Klara Klimesova, Pavel Rossmann, Jakub Mrazek, Jan Kopecny, Michaela Hornova, Dagmar Srutkova, Tomas Hudcovic, Jakub Ridl, Helena Tlaskalova-Hogenova
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b6c878bdf45341cd899f2a34fe2f61bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6c878bdf45341cd899f2a34fe2f61bb
record_format	dspace
spelling	oai:doaj.org-article:b6c878bdf45341cd899f2a34fe2f61bb2021-11-18T07:33:43ZLysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.1932-620310.1371/journal.pone.0027961https://doaj.org/article/b6c878bdf45341cd899f2a34fe2f61bb2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22132181/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD.<h4>Methodology/principal findings</h4>The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR. We also measured CD4(+)FoxP3(+) regulatory T cells proportion by FACS analysis, microbiota composition by pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the numbers of CD4(+)FoxP3(+) regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory cytokines TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer's patches and large intestine, and changes the gut microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-α expression in RAW 264.7 cell line by down-regulating the NF-κB signaling pathway.<h4>Conclusion/significance</h4>Our study provided evidence that even non-living probiotic bacteria can prevent the development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation of gut microenvironment.Zuzana ZakostelskaMiloslav KverkaKlara KlimesovaPavel RossmannJakub MrazekJan KopecnyMichaela HornovaDagmar SrutkovaTomas HudcovicJakub RidlHelena Tlaskalova-HogenovaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 11, p e27961 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zuzana Zakostelska Miloslav Kverka Klara Klimesova Pavel Rossmann Jakub Mrazek Jan Kopecny Michaela Hornova Dagmar Srutkova Tomas Hudcovic Jakub Ridl Helena Tlaskalova-Hogenova Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
description	<h4>Background</h4>Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD.<h4>Methodology/principal findings</h4>The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR. We also measured CD4(+)FoxP3(+) regulatory T cells proportion by FACS analysis, microbiota composition by pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the numbers of CD4(+)FoxP3(+) regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory cytokines TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer's patches and large intestine, and changes the gut microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-α expression in RAW 264.7 cell line by down-regulating the NF-κB signaling pathway.<h4>Conclusion/significance</h4>Our study provided evidence that even non-living probiotic bacteria can prevent the development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation of gut microenvironment.
format	article
author	Zuzana Zakostelska Miloslav Kverka Klara Klimesova Pavel Rossmann Jakub Mrazek Jan Kopecny Michaela Hornova Dagmar Srutkova Tomas Hudcovic Jakub Ridl Helena Tlaskalova-Hogenova
author_facet	Zuzana Zakostelska Miloslav Kverka Klara Klimesova Pavel Rossmann Jakub Mrazek Jan Kopecny Michaela Hornova Dagmar Srutkova Tomas Hudcovic Jakub Ridl Helena Tlaskalova-Hogenova
author_sort	Zuzana Zakostelska
title	Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
title_short	Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
title_full	Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
title_fullStr	Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
title_full_unstemmed	Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
title_sort	lysate of probiotic lactobacillus casei dn-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/b6c878bdf45341cd899f2a34fe2f61bb
work_keys_str_mv	AT zuzanazakostelska lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT miloslavkverka lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT klaraklimesova lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT pavelrossmann lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT jakubmrazek lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT jankopecny lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT michaelahornova lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT dagmarsrutkova lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT tomashudcovic lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT jakubridl lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment AT helenatlaskalovahogenova lysateofprobioticlactobacilluscaseidn114001amelioratescolitisbystrengtheningthegutbarrierfunctionandchangingthegutmicroenvironment
_version_	1718423309957201920

Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.

Ejemplares similares